Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $6.6 Million - $9.04 Million
-177,134 Reduced 29.82%
416,830 $16.7 Million
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $64,314 - $92,064
1,552 Added 0.26%
593,964 $25.4 Million
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $228,849 - $300,317
-5,801 Reduced 0.97%
592,412 $28.4 Million
Q3 2022

Nov 14, 2022

SELL
$27.8 - $40.12 $3,336 - $4,814
-120 Reduced 0.02%
598,213 $22.5 Million
Q2 2022

Aug 12, 2022

SELL
$26.03 - $67.04 $1.56 Million - $4.01 Million
-59,812 Reduced 9.09%
598,333 $16.5 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $4.47 Million - $6.29 Million
106,047 Added 19.21%
658,145 $35.8 Million
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $14 Million - $23.8 Million
378,888 Added 218.74%
552,098 $32.3 Million
Q3 2021

Nov 12, 2021

BUY
$29.27 - $43.71 $5.07 Million - $7.57 Million
173,210 New
173,210 $6.85 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.